Treatment Outcomes of Alternating Chemoradiotherapy for Nasopharyngeal Carcinoma

2015 
Purpose: The aim of this study was to analyze the treatment outcomes of alternating chemoradiotherapy (ACRT) for nasopharyngeal carcinoma (NPC) and to assess the safety and ef 昀c c of this treatment. Materials and Methods: Twelve patients with stage II–IVB NPC were treated with ACRT in our hospital be‐ tween 2005 and 2011. The radiotherapy period was divided into two components. In the 昀rst half, patients re‐ ceived 36 Gy to the whole neck 昀eld. In the second half, patients received 30~34.2Gy to the shrinking 昀eld to the primary and involved lymph nodes. A course of chemotherapy comprised of 昀uorour cil at a dose of 800 mg/m 2 /day was administered for 5 days (day 1–5), and cisplatin at 50 mg/m 2 /day was administered for 2 days (day 6–7). A total of three courses of chemotherapy were performed systemically before starting radiotherapy, after completing the 昀rst half of radiotherapy and after completing the second half of radiotherapy. Results: The planned radiation dose was achieved for all patients. Ten of the 12 patients completed the three courses of chemotherapy as planned. The remaining two patients completed only two courses because they re‐ fused, not due to adverse events. The 昀ve- e r overall survival rate was 83%, the progression-free survival rate was 67%, the locoregional progression-free survival rate was 75%, and the distant-metastasis free survival rate was 92%. With regard to acute adverse events, the incidence of grade ≧3 hematotoxicity was 33%, and the nonhematotoxicity event was only one case of grade 3 mucositis. No late adverse events of grade ≧3 occurred. Conclusion: ACRT offered an excellent completion rate and could be safely conducted. Although a limited numbers of subjects were considered in this study, the outcomes of ACRT were favorable in terms of safety and ef 昀c c .
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    15
    References
    0
    Citations
    NaN
    KQI
    []